ProTEC-USA Announces Expanded Medical Gown Manufacturing Capabilities

ProTEC-USA has announced the debut of a new, state of the art production work cell that will expand and enhance its capacity to produce EZDoff medical gowns for healthcare and other critical industries.

A subsidiary of Troy, Michigan-based Cadillac Products, Inc., in-house extrusion, film converting and gown manufacturing capabilities from the company’s facilities in the USA allow ProTEC-USA to serve as a strategic, domestic supply chain partner, delivering high-quality gowns with volume-level pricing.

“COVID-19 exacerbated market demands that were already growing prior to the pandemic,” said Don Lowe, Spokesperson, ProTEC-USA. “This investment from the company in upgrades and enhancements to production lines and equipment will boost our capacity in order to better meet demand.

The new, proprietary work cell was completely designed and built inhouse, addressing all the needs for quality control and optimal cost. These gowns will be available in three color options—blue, yellow or white—and will also be available with level 1, 2 or 3 compliance, based on the depth of protective needs of the user.

“EZDoff gowns are designed to not only maintain effectiveness and mitigate potential self-contamination, but also to be mindful of the manner in which the gowns are donned and doffed in sequence with other PPE,” said Lowe. “Without touching the outside surface of the EZDoff gown to remove it, the wearer is protected against consequential contamination.”

EZDoff gowns offer several features and benefits for wearers, including:

Perforated rear yoke for safe, easy doffing of medical gowns
Sleeve with thumb loop for full arm and wrist protection, simultaneous glove donning
Apron closure to maintain the user’s coolness during work performance
Compliance with all AAMI and FDA specifications and requirements

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.